[{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"EuMentis Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Akos Biosciences"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis Therapeutics \/ Kerry Murphy"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : Under the terms of the licensing agreement, Aries will gain the rights to Enveric’s patented topical product EV102 for the clinical development of radiation dermatitis treatment.

                          Product Name : EV102

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 15, 2024

                          Lead Product(s) : EV102

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Discovery

                          Sponsor : Akos Biosciences

                          Deal Size : $61.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia and plans to advance its lead NMDA receptor antagonist candidate for ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 02, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Discovery

                          Sponsor : Department of Defense

                          Deal Size : $3.0 million

                          Deal Type : Funding

                          blank

                          03

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.

                          Product Name : KCC2

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 28, 2020

                          Lead Product(s) : KCC2

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Discovery

                          Sponsor : Kerry Murphy

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          04

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Discovery

                          Sponsor : Distributed Bio

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank